Shifting emphasis from pharmacogenomics to theragnostics

Nat Biotechnol. 2006 Aug;24(8):942-6. doi: 10.1038/nbt0806-942.

Authors

Vural Ozdemir¹, Bryn Williams-Jones, Stephen J Glatt, Ming T Tsuang, James B Lohr, Christopher Reist

Affiliation

¹ Biomarker and Clinical Pharmacology Unit, VA Long Beach Healthcare System, Southern California Institute for Research and Education, University of California, Irvine, CA, USA. vural.ozdemir@med.va.gov

Abstract

What will be the role of theragnostic patents in upstream and downstream biomarker research?

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review

MeSH terms

Drug Delivery Systems / methods*
Drug Design*
Drug Therapy / methods
Drug Therapy / trends
Pharmacogenetics / methods*
Pharmacogenetics / trends*